Your browser doesn't support javascript.
loading
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Janjigian, Yelena Y; Kawazoe, Akihito; Yañez, Patricio; Li, Ning; Lonardi, Sara; Kolesnik, Oleksii; Barajas, Olga; Bai, Yuxian; Shen, Lin; Tang, Yong; Wyrwicz, Lucjan S; Xu, Jianming; Shitara, Kohei; Qin, Shukui; Van Cutsem, Eric; Tabernero, Josep; Li, Lie; Shah, Sukrut; Bhagia, Pooja; Chung, Hyun Cheol.
Afiliación
  • Janjigian YY; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. janjigiy@mskcc.org.
  • Kawazoe A; National Cancer Hospital East, Kashiwa, Japan.
  • Yañez P; Universidad de La Frontera, James Lind Cancer Research Center, Temuco, Chile.
  • Li N; Henan Cancer Hospital, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Lonardi S; Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.
  • Kolesnik O; Medical Center 'Oncolife', Zaporizhzhia, Ukraine.
  • Barajas O; Arturo López Pérez Foundation, Santiago, Chile.
  • Bai Y; Harbin Medical University Cancer Hospital, Harbin, China.
  • Shen L; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.
  • Tang Y; Cancer Hospital Affiliated to Xinjiang Medical University, Xinjiang, China.
  • Wyrwicz LS; Maria Sklodowska-Curie National Cancer Research Institute, Warsaw, Poland.
  • Xu J; The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Shitara K; National Cancer Hospital East, Kashiwa, Japan.
  • Qin S; Cancer Center of People's Liberation Army, Nanjing, China.
  • Van Cutsem E; University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium.
  • Tabernero J; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain.
  • Li L; Merck & Co., Kenilworth, NJ, USA.
  • Shah S; Merck & Co., Kenilworth, NJ, USA.
  • Bhagia P; Merck & Co., Kenilworth, NJ, USA.
  • Chung HC; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Nature ; 600(7890): 727-730, 2021 12.
Article en En | MEDLINE | ID: mdl-34912120
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Receptor ErbB-2 / Anticuerpos Monoclonales Humanizados / Receptor de Muerte Celular Programada 1 / Trastuzumab Tipo de estudio: Clinical_trials / Guideline Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Receptor ErbB-2 / Anticuerpos Monoclonales Humanizados / Receptor de Muerte Celular Programada 1 / Trastuzumab Tipo de estudio: Clinical_trials / Guideline Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article